Somnomed Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.
|Primary activities||Development, manufacturing and marketing of innovative dental and medical products, with a focus on sleep-disordered breathing|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||20 Clarke Street Level 3 Crows Nest NSW 2065 Australia|
|Phone / Fax||61 2 9467 0400 / 61 2 9467 0467|
|Share registry||BOARDROOM PTY LIMITED|
Somnomed does not pay dividends.
As of May 2021, following are the company executives and directors listed on Somnomed.
|Mr. Neil Verdal-Austin||CEO, MD & Director||472.53k|
|Mr. HervÃ© FiÃ©vet||Chief Financial Officer||256.17k|
|Mr. Mark Harding||VP of Global Marketing||267.39k|
|Mr. Martin Weiland||Exec. VP of Sales and Marketing - Europe||451.86k|
|Mr. Matthew Conlon||Exec. VP Sales & Marketing - North America||410.08k|
|Dr. Jagdeep Bijwadia||Chief Medical Officer|
|Mr. Terence A. Flitcroft||Company Sec.||61|
|Dr. Peter Spencer MBA Ph.D., MAICD||Gen. Mang. of Operations||64|
|Mr. Christopher Bedford||VP of Global Production and Product Devel.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Somnomed is 170.48M and its enterprise value is 156.71M. The enterprise value to revenue ratio of SOM is 2.86.
The SOM's stocks Beta value is 1.23 making it 23% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Somnomed (SOM)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Somnomed (ASX:SOM) Frequently Asked Questions
1. What is Somnomed's Stock Symbol?
Somnomed trades on ASX under the ticker symbol "SOM".
2. What is Somnomed's stock price today?
One share of SOM stock can currently be purchased for approximately $2.06.
3. How can I contact Somnomed?
Somnomed's mailing address is 20 Clarke Street Level 3 Crows Nest NSW 2065 Australia. The company can be reached via phone at 61 2 9467 0400.
4. What is Somnomed's official website?
The official website of Somnomed is http://somnomed.com/au/.
5. Which share registry manages Somnomed's stock?
Somnomed's stock is managed by BOARDROOM PTY LIMITED.